Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan in PAH Secondary to IPF
NCT00625469Phase 4Withdrawn
- Start
- Oct 2007
- Primary completion
- Jun 2009
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of bosentan in pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF). Planned start Oct 2007; status: withdrawn.
02
Drugs
bosentan
03
Conditions
pulmonary arterial hypertension (PAH)idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT00625469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00625469.